The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-08-19 DOI:10.1038/s41571-024-00938-3

Fatemeh Ardeshir-Larijani, Suresh S. Ramalingam

引用次数: 0

Abstract

In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.

查看原文本刊更多论文

MARIPOSA 试验--对治疗表皮生长因子受体突变型 NSCLC 的影响

过去两年，晚期表皮生长因子受体突变非小细胞肺癌的治疗取得了重大进展。最近的研究表明，第三代酪氨酸激酶抑制剂与化疗或针对表皮生长因子受体（EGFR）和MET的双特异性抗体联合使用可带来更多益处。在此，我们总结了这些进展及其对临床实践的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.